We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+62.1%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.18B
AUM Growth
+$1.19B
Cap. Flow
+$143M
Cap. Flow %
3.41%
Top 10 Hldgs %
48.69%
Holding
88
New
15
Increased
28
Reduced
14
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$127M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$72.2M
3
BSX icon
Boston Scientific
BSX
+$68.3M
4
APRE icon
Aprea Therapeutics
APRE
+$62.5M
5
UNH icon
UnitedHealth
UNH
+$52.9M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$155M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$114M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$87.2M
4
CELG
Celgene Corp
CELG
+$55.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$49.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Industrials 0.33%
3 Technology 0%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$293M 7.01%
4,709,498
-71,400
-1% -$3.39M
ALLK
2
DELISTED
Allakos
ALLK
$289M 6.92%
3,033,526
-43,602
-1% -$3.83M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$246M 5.87%
25,209,964
+2,419,830
+11% +$22.2M
FATE icon
4
Fate Therapeutics
FATE
$291M
$220M 5.25%
11,216,809
– –
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$215M 5.15%
8,746,033
+109,100
+1% +$1.62M
ARGX icon
6
argenx
ARGX
$64B
$185M 4.43%
1,153,232
+72,800
+7% +$9.85M
QURE icon
7
uniQure
QURE
$3.38B
$183M 4.38%
2,553,325
+143,200
+6% +$7.86M
PRNB
8
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$149M 3.57%
2,722,388
+1,932,382
+245% +$72.2M
BIIB icon
9
Biogen
BIIB
$32.3B
$136M 3.25%
+457,500
New +$127M
IGMS
10
DELISTED
IGM Biosciences
IGMS
$120M 2.87%
3,144,000
– –
BMY icon
11
Bristol-Myers Squibb
BMY
$136B
$116M 2.76%
1,800,800
-451,800
-20% -$25.9M
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$110M 2.64%
939,164
+295,300
+46% +$29.2M
FTSV
13
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$109M 2.61%
2,770,842
+1,143,344
+70% +$18.4M
APRE icon
14
Aprea Therapeutics
APRE
$10.6M
$104M 2.49%
+113,436
New +$62.5M
RGNX icon
15
Regenxbio
RGNX
$638M
$103M 2.46%
2,508,386
+145,900
+6% +$5.76M
CNC icon
16
Centene
CNC
$32B
$97.6M 2.33%
1,552,598
+742,100
+92% +$40.3M
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
$80.4M 1.92%
2,129,100
+51,400
+2% +$1.92M
ATRA icon
18
Atara Biotherapeutics
ATRA
$92.3M
$76.6M 1.83%
185,943
+5,154
+3% +$1.78M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$74.7M 1.79%
14,639,960
+23,400
+0.2% +$79.4K
BSX icon
20
Boston Scientific
BSX
$67.9B
$73.8M 1.76%
+1,631,200
New +$68.3M
TNDM icon
21
Tandem Diabetes Care
TNDM
$1.49B
$69.9M 1.67%
1,172,232
+11,831
+1% +$730K
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$63.9M 1.53%
+3,237,700
New +$51.8M
KRYS icon
23
Krystal Biotech
KRYS
$10.4B
$60.4M 1.44%
1,090,200
+11,900
+1% +$584K
UNH icon
24
UnitedHealth
UNH
$353B
$59.7M 1.43%
203,100
+202,129
+20,817% +$52.9M
NVS icon
25
Novartis
NVS
$292B
$54.3M 1.3%
+573,100
New +$51.4M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2019 Portfolio in Review

As of Q4 2019, Redmile Group held 88 positions worth $4.18B, up 40% from $2.99B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group deployed $143M of net new capital in Q4 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Biogen: 457,500 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Audentes Therapeutics, Inc, an estimated $87.2M trimmed.

  • Redmile Group's largest Q4 2019 buy was Biogen: 457,500 shares worth $136M.
  • Redmile Group added most to Principia Biopharma Inc. Common Stock in Q4 2019, an estimated $72.2M increase.
  • Redmile Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $87.2M.
  • Redmile Group fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $155M.
  • Redmile Group's ten largest holdings make up 49% of its $4.18B portfolio in Q4 2019.
  • Redmile Group opened 15 new positions and closed 24 in Q4 2019.
  • Redmile Group's portfolio value rose 40% quarter-over-quarter to $4.18B.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.